Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets.
OBJECTIVE
The aim of this study is to search for new therapeutic targets for atypical teratoid-rhabdoid tumors (ATRT).


METHODS
To achieve this, we compared the expression of 365 microRNAs among ATRT, medulloblastomas, and normal brain.


RESULTS
MiR-221 and miR-222 were within the top differentially expressed microRNAs. The deregulated expression of miR221/222 was demonstrated to inhibit the expression of the tumor suppressor and inhibitor of cell cycle p27(Kip1). Here, we demonstrated the negative regulation of p27(Kip1) by miR-221/222 in ATRT using microarray, real-time reverse transcriptase polymerase chain reaction, and immunohistochemistry.


CONCLUSIONS
As anti-miR therapy was recently proposed as an alternative treatment for cancer, these findings suggest that anti-miR-221/222 therapy might have therapeutic potential in ATRT.
Sredni
Simone Treiger
ST
Cancer Biology and Epigenomics Program, Children's Memorial Research Center, Department of Pediatrics, Feinberg School of Medicine, Children's Memorial Hospital, 2300 Children's Plaza, Chicago, IL 60614, USA. ssredni@childrensmemorial.org
Bonaldo
Maria de Fátima
Mde F
Costa
Fabrício Falconi
FF
Huang
Chiang-Ching
CC
Hamm
Christopher Allan
CA
Rajaram
Veena
V
Tomita
Tadanori
T
Goldman
Stewart
S
Bischof
Jared Marshall
JM
Soares
Marcelo Bento
MB
D001921:Brain / Q000378:metabolism*; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D002868:Chromosomal Proteins, Non-Histone / Q000378:metabolism; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D035683:MicroRNAs / Q000378:metabolism*; D020411:Oligonucleotide Array Sequence Analysis; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D018335:Rhabdoid Tumor / Q000188:drug therapy / Q000378:metabolism*; D000071796:SMARCB1 Protein; D013724:Teratoma / Q000188:drug therapy / Q000378:metabolism*; D014157:Transcription Factors / Q000378:metabolism
D002868:Chromosomal Proteins, Non-Histone; D050760:Cyclin-Dependent Kinase Inhibitor p27; D004268:DNA-Binding Proteins; D035683:MicroRNAs; D012333:RNA, Messenger; D000071796:SMARCB1 Protein; D014157:Transcription Factors; C525709:MIR221, human; C525710:MIR222, human; C513266:SMARCB1 protein, human